Table 1 Clinical features stratified by hsa_circ_0001020, hsa_circ_0036683 and hsa_circ_0058087 expression.

From: Genome-wide identification and characterization of circular RNA in resected hepatocellular carcinoma and background liver tissue

Variables		All	hsa_circ_0001020 expression			hsa_circ_0036683 expression			hsa_circ_0058087 expression			MV
Variables		All	Low (n = 122)	High (n = 98)	p	Low (n = 36)	High (n = 170)	p	Low (n = 25)	High (n = 170)	p	MV
Age (years)	Median (range)	65 (21–84)	64 (21–80)	65 (37–84)	0.323	64 (43–78)	65 (21–84)	0.657	67 (46–72)	65 (21–84)	0.152	0
Sex	Female	34	13	20	0.057	3	28	0.306	3	27	0.772	0
Sex	Male	199	109	78		33	142		22	143
Virus infection	HCV and HBV	1	1	0	0.586	0	0	1	0	1	0.718	0
	HBV	54	31	20		8	39		6	43
	HCV	142	70	64		23	105		17	101
	Non-HBV/HCV	36	20	14		5	26		2	25
Albumin (g/dL)	Median (range)	3.9 (2.3–4.9)	3.9 (2.6–4.9)	3.9 (2.3–4.8)	0.927	3.9 (2.3–4.9)	3.9 (2.4–4.8)	0.693	4.0 (2.8–4.8)	3.9 (2.3–4.9)	0.985	2
Total bilirubin (mg/dL)	Median (range)	0.7 (0.2–2.3)	0.7 (0.3–2.3)	0.7 (0.2–2.3)	0.669	0.7 (0.4–2.3)	0.7 (0.2–2.0)	0.942	0.7 (0.4–1.8)	0.7 (0.2–2.3)	0.420	2
PT (%)	Median (range)	86.9 (46.9–138)	86.3 (46.5–138.0)	86.7 (59.3–132.0)	0.32	88.9 (64.0–116.1)	85.2 (46.5–132.0)	0.979	87.5 (62.8–102.7)	84.0 (46.5–138.0)	0.918	3
ICG-R15 (%)	Median (range)	11.5 (0.2–70.5)	11.5 (0.2–39.6)	11.4 (3.2–70.5)	0.677	12.8 (0.2–39.6)	11.4 (1.6–70.5)	0.175	12.8 (3.0–35.1)	11.1 (1.6–70.5)	0.426	51
AFP (ng/mL)	Median (range)	24.0 (0.8–119,923)	39 (1.2–119,923)	12.0 (0.8–36,026)	0.003	21.0 (2.1–36,978)	22.5 (0.8–43,659)	0.241	39.0 (1.9–3441)	23.0 (1.0–119,923)	0.485	3
PIVKA-II (mAU/mL)	Median (range)	44.0 (0–159,820)	49.0 (0–159,820)	39.0 (0–91,960)	0.962	126.0 (0.1–159,820)	36.5 (0–91,960)	0.027	52.0 (0.1–26,877)	34.5(0–159,820)	0.164	28
Child–Pugh classification	A	199	104	87	0.685	33	147	0.580	23	144	0.539	2
Child–Pugh classification	B	32	17	11		3	22		2	25
Liver damage	A	175	90	77	1	27	129	0.659	17	129	0.446	7
Liver damage	B	51	26	21		9	35		7	37
Tumor multiplicity	Solitary	172	91	74	1	27	130	0.832	22	120	0.091	0
Tumor multiplicity	Multiple	61	31	24		9	40		3	50
Tumor size (cm)	Median (range)	3.6 (0.15–15)	4.4 (1.0–15)	3.2 (0.15–12)	0.004	5.0 (1.0–15)	3.5 (0.15–12)	0.006	4.3 (1.5–9)	3.5 (0.15–15)	0.933	73
Differentiation	Well or moderate	212	10	5	0.426	32	12	0.726	21	159	0.209	6
Differentiation	Poorly	15	110	93		3	157		3	10
Growth form	Expansive	193	101	81	0.851	28	141	0.453	20	142	0.548	6
Growth form	Infiltrative	34	19	14		7	25		5	24
Formation of capsule	Positive	166	90	68	0.547	26	121	1	20	123	0.479	0
Formation of capsule	Negative	67	32	30		10	49		5	47
Infiltration to capsule	Negative	93	49	37	0.781	16	67	0.571	8	67	0.658	1
Infiltration to capsule	Positive	139	72	61		19	103		16	103
Septal formation	Positive	158	89	63	0.135	23	118	1	17	118	1	4
Septal formation	Negative	71	30	34		10	51		7	49
Serosal invasion	Negative	162	81	72	0.085	25	117	0.282	21	112	0.449	23
Serosal invasion	Positive	48	30	14		11	33		4	36
Portal vein or hepatic vein invasion	Negative	171	82	82	0.008	22	131	0.059	17	128	0.465	0
Portal vein or hepatic vein invasion	Positive	62	40	16		14	39		8	42
Surgical margin	Negative	179	92	76	0.743	25	128	0.520	19	125	1	4
Surgical margin	Positive	50	28	20		10	39		6	41
Stage	I	33	14	19	0.010	3	26	0.186	3	27	0.549	3
	II	110	51	55		15	87		14	75
	III	59	38	15		11	39		7	44
	IV	28	17	9		7	16		1	22

n number, HBV hepatitis B virus, HCV hepatitis C virus, PT prothrombin time, ICG-R15 retention rate of indocyanine green 15 min after administration, AFP alpha-fetoprotein, PIVKA-II protein induced by vitamin K absence or antagonist-II, MV missing value.

Back to article page

Table 1 Clinical features stratified by hsa_circ_0001020, hsa_circ_0036683 and hsa_circ_0058087 expression.

Search

Quick links